Cystic Fibrosis Clinical Trial
Official title:
Fidgety Movements Analysis in Infants With Cystic Fibrosis
| NCT number | NCT03381157 |
| Other study ID # | AkmerMutlu |
| Secondary ID | |
| Status | Completed |
| Phase | |
| First received | |
| Last updated | |
| Start date | October 2, 2017 |
| Est. completion date | February 2, 2019 |
| Verified date | July 2019 |
| Source | Hacettepe University |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
Very low birth weight infants who are at risk for chronic lung diseases may also be at risk
for brain anomalies such as increased echogenicity, leukomalacia and intracranial hemorrhage.
Infants with bronchopulmonary dysplasia have been reported to have worse neurodevelopmental
outcomes than healthy infants. It has also been pointed out that babies with prolonged and
recurrent apneas during sleep may have weak General Movements (GMs) repertoire.
It has been mentioned that motor development retardation may also occur in neurodevelopmental
diseases, genetic diseases and chronic lung diseases, as well as in cystic fibrosis. In
infants with cystic fibrosis, motor development may be affected by increased incidence of
hospitalization, previous infections, malnutrition, respiratory and digestive system
disorders. There is no research done with GMs assessment to determine motor dysfunction in
infants with cystic fibrosis and this topic is open to research.
Having more information about the motor development of babies by determining the motor
characteristics and motor performance of infants with cystic fibrosis, it may be possible to
start the disease-specific physiotherapy and rehabilitation programs as early as possible.
For this reasons, in the study the investigators aimed to investigate the characteristics of
GMs in the "Fidgety" period of 3-5 month term infants diagnosed with cystic fibrosis, to
determine the motor performances and to investigate the relation between the GMs
characteristics and the features of the disease.
The hypotheses the investigators have set for this study are listed below;
Ho: Spontaneous movements of the "Fidgety" period of infants diagnosed with 3-5 months of
cystic fibrosis are not different from normal infants.
H1: Spontaneous movements of "Fidgety" period of infants diagnosed with cystic fibrosis
between 3-5 months are different from normal infants.
| Status | Completed |
| Enrollment | 38 |
| Est. completion date | February 2, 2019 |
| Est. primary completion date | February 2, 2019 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 3 Months to 5 Months |
| Eligibility |
Inclusion Criteria: - Being diagnosed with cystic fibrosis - Being between the postterm 3rd and 5th months Exclusion Criteria: - Having congenital anomalies, - Having an ongoing infection, - Risk of high or low neurological impairment due to perinatal stroke, perinatal asphyxia, intra / peri-ventricular hemorrhage (IVH / PVL), bronchopulmonary dysplasia, - Fidgety movements evaluation results; being abnormal (AF), sporadic (F +/-) or non-F (F-) - Baby's family does not want to be involved in the work |
| Country | Name | City | State |
|---|---|---|---|
| Turkey | Hacettepe University, Faculty of Health Sciences, Departmant of Pyhsiotherapy and Rehabilitation | Ankara |
| Lead Sponsor | Collaborator |
|---|---|
| Hacettepe University |
Turkey,
Einspieler C, Peharz R, Marschik PB. Fidgety movements - tiny in appearance, but huge in impact. J Pediatr (Rio J). 2016 May-Jun;92(3 Suppl 1):S64-70. doi: 10.1016/j.jped.2015.12.003. Epub 2016 Mar 17. Review. — View Citation
Herrero D, Einspieler C, Panvequio Aizawa CY, Mutlu A, Yang H, Nogolová A, Pansy J, Nielsen-Saines K, Marschik PB; GenGM Study Group. The motor repertoire in 3- to 5-month old infants with Down syndrome. Res Dev Disabil. 2017 Aug;67:1-8. doi: 10.1016/j.ridd.2017.05.006. Epub 2017 Jun 3. — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Motor Optimality Score (MOS) | The MOS has a max. value of 28 (for the best possible performance) and a min. value of 5. The score sheet comprises the following five sub-categories: fidgety movements, age-adequacy of motor repertoire, quality of movement patterns other than fidgety movements, posture, and overall quality of the motor repertoire. Fidgety Movements; normal fidgety: 12 points, abnormal fidgety: 4 points and sporadic fidgety: 1 points Age-adequacy of motor repertoire; normal motor repertoire: 4 points, decreased motor repertoire: 2 points, non age-adequacy of motor repertoire: 1 points Quality of movement patterns other than fidgety movements; normal movement patterns: 4 points, equal normal and abnormal movement patterns: 2 points, abnormal movement patterns: 1 points Posture; normal posture: 4 points, equal normal and abnormal posture: 2 points, abnormal posture: 1 points Overall quality of the motor repertoire; normal: 4 points, abnormal: 2 points, cramped-synchronized: 1 points |
45 minute for each patient |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04696198 -
Thoracic Mobility in Cystic Fibrosis Care
|
N/A | |
| Completed |
NCT00803205 -
Study of Ataluren (PTC124™) in Cystic Fibrosis
|
Phase 3 | |
| Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
| Completed |
NCT03601637 -
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
|
Phase 3 | |
| Terminated |
NCT02769637 -
Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
|
||
| Recruiting |
NCT06032273 -
Lung Transplant READY CF 2: CARING CF Ancillary RCT
|
N/A | |
| Recruiting |
NCT06012084 -
The Development and Evaluation of iCF-PWR for Healthy Siblings of Individuals With Cystic Fibrosis
|
N/A | |
| Recruiting |
NCT06030206 -
Lung Transplant READY CF 2: A Multi-site RCT
|
N/A | |
| Recruiting |
NCT05392855 -
Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF)
|
N/A | |
| Recruiting |
NCT06088485 -
The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
|
||
| Recruiting |
NCT04039087 -
Sildenafil Exercise: Role of PDE5 Inhibition
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04056702 -
Impact of Triple Combination CFTR Therapy on Sinus Disease.
|
||
| Completed |
NCT04058548 -
Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation
|
N/A | |
| Completed |
NCT04038710 -
Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
|
||
| Completed |
NCT03637504 -
Feasibility of a Mobile Medication Plan Application in CF Patient Care
|
N/A | |
| Recruiting |
NCT03506061 -
Trikafta in Cystic Fibrosis Patients
|
Phase 2 | |
| Completed |
NCT03566550 -
Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
|
||
| Recruiting |
NCT04828382 -
Prospective Study of Pregnancy in Women With Cystic Fibrosis
|
||
| Completed |
NCT04568980 -
Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
|
||
| Recruiting |
NCT04010253 -
Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis
|
N/A |